A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007

Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Despite a multimodal treatment response, survival for GBM patients remains between 12 and 15 months. Anti‐ELTD1 antibody therapy is effective in decreasing tumour volumes and increasing animal survival in an orthotopic G...

Descripción completa

Detalles Bibliográficos
Autores principales: Zalles, Michelle, Smith, Nataliya, Saunders, Debra, Lerner, Megan, Fung, Kar‐Ming, Battiste, James, Towner, Rheal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743651/
https://www.ncbi.nlm.nih.gov/pubmed/34910361
http://dx.doi.org/10.1111/jcmm.17133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743651/
https://www.ncbi.nlm.nih.gov/pubmed/34910361
http://dx.doi.org/10.1111/jcmm.17133

Ejemplares similares